{"id":59330,"date":"2026-03-12T12:58:15","date_gmt":"2026-03-12T04:58:15","guid":{"rendered":"https:\/\/flcube.com\/?p=59330"},"modified":"2026-03-12T12:58:16","modified_gmt":"2026-03-12T04:58:16","slug":"huadong-medicines-hdm2017-wins-fda-orphan-drug-designation-cdh17-adc-targets-three-gastrointestinal-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59330","title":{"rendered":"Huadong Medicine&#8217;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that <strong>HDM2017<\/strong>, its <strong>independently developed CDH17-targeting antibody-drug conjugate (ADC)<\/strong>, has received <strong>U.S. FDA Orphan Drug Designation (ODD)<\/strong> for <strong>three indications: biliary tract cancer, gastric cancer, and pancreatic cancer<\/strong>. The <strong>novel ADC<\/strong>, which utilizes <strong>antigen-mediated internalization<\/strong> and <strong>bystander activity<\/strong> to enhance tumor killing, previously secured <strong>IND approvals from both NMPA and FDA in September 2025<\/strong>. The <strong>triple ODD<\/strong> validates Huadong&#8217;s <strong>innovation capabilities<\/strong> and accelerates development in <strong>high-unmet-need gastrointestinal malignancies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Orphan Drug Designation (ODD) \u2013 three indications<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HDM2017 for injection<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Antibody-drug conjugate (ADC) \u2013 Category 1 innovative biological drug<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Cadherin 17 (CDH17\/LI-cadherin)<\/td><\/tr><tr><td><strong>Indications (ODD)<\/strong><\/td><td>\u2022 Biliary tract cancer<br>\u2022 Gastric cancer<br>\u2022 Pancreatic cancer<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Huadong Medicine Co., Ltd (SHE: 000963) \u2013 independently developed<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>IND cleared by NMPA and FDA (September 2025) for advanced malignant solid tumors<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>11\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>HDM2017 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Cadherin 17 (CDH17\/LI-cadherin) \u2013 cell adhesion molecule overexpressed in GI cancers<\/td><\/tr><tr><td><strong>Architecture<\/strong><\/td><td>Anti-CDH17 antibody + cleavable linker + cytotoxic payload<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>\u2022 <strong>Targeting:<\/strong> Antibody identifies CDH17-positive tumor surface antigens<br>\u2022 <strong>Internalization:<\/strong> Antigen-mediated entry into tumor cells<br>\u2022 <strong>Payload Release:<\/strong> Intracellular linker cleavage releases cytotoxin<br>\u2022 <strong>Bystander Effect:<\/strong> Membrane-permeable payload kills neighboring antigen-negative cells<\/td><\/tr><tr><td><strong>Preclinical Profile<\/strong><\/td><td>\u2022 Excellent drug-like properties<br>\u2022 Potent anti-tumor activity in CDH17-positive colorectal, pancreatic, gastric models<br>\u2022 Well-tolerated in animal studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>CDH17 Biology:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expression Pattern:<\/strong> Highly expressed in gastrointestinal epithelium; upregulated in biliary, gastric, pancreatic, and colorectal cancers<\/li>\n\n\n\n<li><strong>Tumor Specificity:<\/strong> Limited normal tissue expression reduces on-target\/off-tumor toxicity risk<\/li>\n\n\n\n<li><strong>Internalization:<\/strong> Efficient antigen-mediated uptake enables effective ADC payload delivery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-value-amp-market-context\">Strategic Value &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Three ODDs<\/strong><\/td><td>Unusual breadth of orphan designation; demonstrates CDH17 relevance across multiple GI malignancies<\/td><\/tr><tr><td><strong>GI Cancer Burden<\/strong><\/td><td>\u2022 Biliary tract: 20,000 U.S. cases\/year<br>\u2022 Gastric: 26,000 U.S. cases\/year<br>\u2022 Pancreatic: 60,000 U.S. cases\/year; all with limited targeted therapy options<\/td><\/tr><tr><td><strong>ODD Benefits<\/strong><\/td><td>7-year market exclusivity; tax credits; waived FDA application fees; protocol assistance<\/td><\/tr><tr><td><strong>Huadong Innovation<\/strong><\/td><td>Second innovative ADC (after HDM2024 EGFR\/HER3) validates biologics platform; traditional pharma pivot to novel modalities<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>U.S.-first development pathway; China NMPA parallel track; potential for Fast Track and Breakthrough Therapy designations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Target<\/th><th>Status<\/th><th>HDM2017 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>AstraZeneca\/Daiichi<\/strong><\/td><td>Enhertu (HER2 ADC)<\/td><td>HER2<\/td><td>Approved (gastric)<\/td><td>CDH17 vs. HER2; different patient population (HER2-negative gastric)<\/td><\/tr><tr><td><strong>Zymeworks\/Jazz<\/strong><\/td><td>Zanidatamab (HER2 bsAb)<\/td><td>HER2<\/td><td>Approved (biliary)<\/td><td>ADC mechanism vs. naked antibody; CDH17 targets non-HER2 population<\/td><\/tr><tr><td><strong>Ipsen\/Exelixis<\/strong><\/td><td>Cabometyx (cabozantinib)<\/td><td>Multi-kinase<\/td><td>Approved (pancreatic, biliary)<\/td><td>Targeted ADC vs. broad kinase inhibition; potentially better tolerability<\/td><\/tr><tr><td><strong>Huadong Medicine<\/strong><\/td><td><strong>HDM2017<\/strong><\/td><td><strong>CDH17<\/strong><\/td><td><strong>Phase I-ready; triple ODD<\/strong><\/td><td><strong>First-in-class CDH17 ADC; novel target with broad GI applicability<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2025-2027 (ongoing)<\/td><td>Safety, tolerability, MTD; CDH17 expression biomarker validation<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2029<\/td><td>Expansion in ODD indications (biliary, gastric, pancreatic); efficacy signals<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2029-2030<\/td><td>Accelerated approval pathway via ODD; potential Breakthrough Therapy designation<\/td><\/tr><tr><td><strong>Combination Studies<\/strong><\/td><td>2028+<\/td><td>With checkpoint inhibitors (PD-1) and chemotherapy backbones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, orphan drug exclusivity value, and competitive positioning for HDM2017. Actual results may differ due to CDH17 target validation in human trials, manufacturing scale-up, and competitive dynamics in GI cancer ADC development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,114,887],"class_list":["post-59330","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong&#039;s innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59330\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong&#039;s innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59330\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T04:58:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T04:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers\",\"datePublished\":\"2026-03-12T04:58:15+00:00\",\"dateModified\":\"2026-03-12T04:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330\"},\"wordCount\":541,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59330#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59330\",\"name\":\"Huadong Medicine's HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-12T04:58:15+00:00\",\"dateModified\":\"2026-03-12T04:58:16+00:00\",\"description\":\"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong's innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59330\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59330#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong's innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59330","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers","og_description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong's innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.","og_url":"https:\/\/flcube.com\/?p=59330","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-12T04:58:15+00:00","article_modified_time":"2026-03-12T04:58:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59330#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59330"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers","datePublished":"2026-03-12T04:58:15+00:00","dateModified":"2026-03-12T04:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59330"},"wordCount":541,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Huadong Medicine","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59330#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59330","url":"https:\/\/flcube.com\/?p=59330","name":"Huadong Medicine's HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-12T04:58:15+00:00","dateModified":"2026-03-12T04:58:16+00:00","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong's innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59330#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59330"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59330#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s HDM2017 Wins FDA Orphan Drug Designation \u2013 CDH17 ADC Targets Three Gastrointestinal Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59330"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59330\/revisions"}],"predecessor-version":[{"id":59331,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59330\/revisions\/59331"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}